Molecular imaging (MI) is reported as an increasingly important diagnostic field for radiologists to focus on. However, molecular imaging should not be considered a new discipline that only adds to today’s clinical practice, or might even replace the traditional, more morphology-oriented diagnosis. Rather, the whole diagnostic concept should be re-considered.
A leading radiologist is forecasting a ‘paradigm shift’ in breast imaging. Dr Peter Brader, from Department of Radiology, Division for Molecular and Gender Imaging, Medical University Vienna, envisages that diagnosis and treatment will move from a ‘one size fits all’ approach to one of personalised molecular medicine by 2025. He also foresees greater use of theranostics with combinations…
Cornelis Van De Velde, Professor of Surgical Oncology at the Leiden University Medical Centre, in the Netherlands, and President of the European Society of Surgical Oncology (ESSO), describes the work and aims of the society within the EU.
The trend towards personalised medicine implies the development of targeted cancer therapy. Tissue based examinations by pathologists play a key role in this trend. However, the relevance is still underestimated as pathologist Professor Manfred Dietel noted in his lecture at the European Forum on Oncology 2010 in Berlin, which explained what pathology already actually renders to targeted cancer…
Yes, cancer research is making rapid progress, but -- how can the transfer of cancer research into successful treatments be accelerated? In Berlin this October, that vexing question was up for discussion during the European Forum on Oncology. Also on the agenda: How best practice approaches to cancer therapy can be adopted throughout the European Union.
Across Europe an estimated 3.2 million new cases and 1.7 million deaths occur annually. By intensified cooperation in research, diagnosis and treatment, enormous advantages can be achieved. To progress the integration of knowledge and skills in this field, the first European Forum on Oncology was held this October in Berlin.
Different tests bring different results, and results of the same types of test vary from laboratory to laboratory. "In the case of test procedures for autoimmune diseases there are incredible discrepancies," confirmed Professor Manfred Herold, head of the Laboratory for Rheumatism at the University Clinic for Internal Medicine One, Innsbruck. The reason: "There are no standards for…
A double-edged sword would be a good analogy for diagnostic imaging in 2010. New ways to utilise imaging technologies are being developed, imaging equipment is doing more, faster than ever, and image processing software is increasingly innovative. Today's radiology exams are ‘slicing’ through the body to reveal anatomy with increasing clarity for better diagnoses and therapeutic treatment…
Biomarkers as the key to prevention and early detection were the subject this autumn at the 7th Annual Congress of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) in Mannheim. For the DGKL president Professor Karl J Lackner MD, Director of the Institute for Clinical Chemistry and Laboratory Medicine at Johannes Gutenberg University, Mainz, the topic is of increasing…
Prior to October’s 3rd Annual Congress of the Austrian Society for Laboratory Medicine and Clinical Chemistry in Salzburg, Austria, laboratory experts conveyed their opinions in an interview with Michael Krassnitzer from European Hospital.
“The current shift of healthcare towards a systemic and holistic understanding of the causes of diseases is a true scientific revolution,“ Prof. Dr. Angela Brand said today at the European Health Forum Gastein (EHFG). Prof. Brand, Director of the European Centre for Public Health Genomics hosted at Maastricht University, added that the “next-generation sequencing technologies are opening…
Ten years ago, molecular biologist Dr Peter H J Riegman set up a unique bio-bank for medical research at the pathology department of Erasmus Medical Centre, Rotterdam, The Netherlands. The Erasmus MC Tissue Bank now holds 30,000 samples from about 15,000 patients. However, when Dr Riegman discusses his bio-bank with international colleagues they do not immediately associate it with a clinic or…
Data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) USA registration trial, involving more than 47,000 women, demonstrate that two human papilloma virus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.
During his Honorary Lecture at the 8th Düsseldorf Breast Cancer Conference in Germany world renowned surgeon and oncologist Prof. Veronesi reflected about the prevention and treatment of breast cancer.
New biomarkers play a key role in individualised tumour therapy. They are important indicators for pathological processes in the body and for the use of adequate cancer drugs. In our European Hospital interview Professor Celso A Reis, from the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP*) in Portugal, discussed the current state of clinical use of…
More than 2 million over the world suffer from Multiple sclerosis (MS). It attacks the central nervous system and eventually renders most patients disabled. Although there is currently no cure, a breakthrough finding from a Tel Aviv University scientist and physician may lead to earlier diagnosis, more effective intervention, and perhaps even a cure for the autoimmune disease.
To mark the first European Parkinson’s Action Day on April 12th, the European Parkinson’s Disease Association (EPDA) announced the launch of a major new investigation into the care of people with Parkinson’s across 36 European countries. Parkinson’s disease is the second most common progressive neurodegenerative condition which affects people from all around the world.
A special feature of this year’s scientific program at ECR 2010 was a joint session organized by the European Association for Nuclear Medicine with the European Society of Radiology. Two speakers representing the EANM took the podium to review developments in nuclear medicine and to challenge colleagues on specific applications.
Since June 2009, the focus of research in the European Network for Cell Imaging and Tracking Expertise (ENCITE) has been on finding biomarkers to aid cell transplantation. Funded with €11 million from the European Commission (EC), this major project that runs until 2013, involves 10 countries. Their work is coordinated by the European Institute for Biomedical Imaging Research (EIBIR) network,…
Molecular imaging, the discipline that unites molecular biology and in vivo imaging technologies to assess biological activity in the body, promises to open up ‘…an entire new universe,’ declared Dr Ralph Weissleder, of the Centre for Molecular Imaging Research at Massachusetts General Hospital, USA, in the journal Radiology. That was just one decade ago. And he was right. It has indeed…
While lower intelligence scores have been associated with a raised risk of cardiovascular disease, no study has so far compared the relative strength of this association with other established risk factors such as obesity, smoking and high blood pressure. Now, a large study has found that lower intelligence scores were associated with higher rates of cardiovascular disease and total mortality at…
Entrepreneur Dr Gunter Pollanz was a central figure in the build-up of charter flights to Israel and in the foundation of MAOF Airlines in Tel Aviv. Later, he also developed important export structures from Israel to Europe. However, in 1997 his life took a dramatic turn when he was diagnosed with lymphoma. Prognosis: Although 54 years old he faced just three more months of life. Today, Dr…
Scientists are closer to discovering why some people respond to breast cancer radiotherapy better than others, according to Breast Cancer Campaign. Dr Laura Smith, at the Leeds Institute of Molecular Medicine, University of Leeds, has been awarded a pilot grant by Breast Cancer Campaign, to study why some types of breast cancers are difficult to destroy with radiotherapy.
For many years we have heard about personalised cancer treatments, understood each cancer patient is different and that 'one size fits all' treatments are not appropriate. We have been told that early diagnosis is the key to successful treatment and that no two patients have the same genetic or biological profile.
This year's AACC, held in conjunction with the Canadian Society for Clinical Chemists, and the Annual Meeting of the American Society for Clinical Laboratory Science, featured around 200 educational sessions and drew in over 18,000 delegates and exhibitors from almost 100 countries.